ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学術雑誌論文等

Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy

https://hiroshima.repo.nii.ac.jp/records/2007292
https://hiroshima.repo.nii.ac.jp/records/2007292
09708462-90cf-4ef7-9cde-f1eb02597171
名前 / ファイル ライセンス アクション
JClinImmunol_40_1065.pdf JClinImmunol_40_1065.pdf (2.5 MB)
Item type デフォルトアイテムタイプ_(フル)(1)
公開日 2023-03-18
タイトル
タイトル Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy
言語 en
作成者 Okada, Satoshi

× Okada, Satoshi

en Okada, Satoshi

Search repository
Asano, Takaki

× Asano, Takaki

en Asano, Takaki

Search repository
Moriya, Kunihiko

× Moriya, Kunihiko

en Moriya, Kunihiko

Search repository
Boisson-Dupuis, Stephanie

× Boisson-Dupuis, Stephanie

en Boisson-Dupuis, Stephanie

Search repository
Kobayashi, Masao

× Kobayashi, Masao

en Kobayashi, Masao

Search repository
Casanova, Jean-Laurent

× Casanova, Jean-Laurent

en Casanova, Jean-Laurent

Search repository
Puel, Anne

× Puel, Anne

en Puel, Anne

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
権利情報 This is not the published version. Please cite only the published version. この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。
主題
主題Scheme Other
主題 STAT1
主題
主題Scheme Other
主題 chronic mucocutaneous candidiasis
主題
主題Scheme Other
主題 Mendelian susceptibility to mycobacterial diseases
主題
主題Scheme Other
主題 gain-of-function
主題
主題Scheme Other
主題 virus
内容記述
内容記述 Heterozygous gain-of-function (GOF) mutations in STAT1 in patients with chronic mucocutaneous candidiasis (CMC) and hypothyroidism were discovered in 2011. CMC is the recurrent or persistent mucocutaneous infection by Candida fungi, and hypothyroidism results from autoimmune thyroiditis. Patients with these diseases develop other infectious diseases, including viral, bacterial, and fungal diseases, and other autoimmune manifestations, including enterocolitis, immune cytopenia, endocrinopathies, and systemic lupus erythematosus. STAT1-GOF mutations are highly penetrant with a median age at onset of 1 year and often underlie an autosomal dominant trait. As many as 105 mutations at 72 residues, including 65 recurrent mutations, have already been reported in more than 400 patients worldwide. The GOF mechanism involves impaired dephosphorylation of STAT1 in the nucleus. Patient cells show enhanced STAT1-dependent responses to type I and II interferons (IFNs) and IL-27. This impairs Th17 cell development, which accounts for CMC. The pathogenesis of autoimmunity likely involves enhanced type I IFN responses, as in other type I interferonopathies. The pathogenesis of other infections, especially those caused by intramacrophagic bacteria and fungi, which are otherwise seen in patients with diminished type II IFN immunity, has remained mysterious. The cumulative survival rates of patients with and without severe disease (invasive infection, cancer, and/or symptomatic aneurysm) at 60 years of age are 31% and 87%, respectively. Severe autoimmunity also worsens the prognosis. The treatment of patients with STAT1-GOF mutations who suffer from severe infectious and autoimmune manifestations relies on hematopoietic stem cell transplantation and/or oral JAK inhibitors.
言語 en
内容記述
内容記述タイプ Other
内容記述 SO acknowledges Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (16H05355 and 19H03620), the Promotion of Joint International Research from the Japan Society for the Promotion of Science (18KK0228), and the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development, AMED. KM acknowledges a fellowship grant from the Japan Foundation for Pediatric Research and the EURO CMC grant (ANR-14-RARE-0005-02). JLC acknowledges the National Institutes of Health grants (grant no. R01AI127564). AP acknowledges grants from the French National Research Agency (ANR) under the “Lymphocyte T helper (Th) cell differentiation in patients with inborn errors of immunity to Mycobacterium and/or Candida species" program (ANR-FNS LTh-MSMD-CMCD, ANR-18-CE93-0008-01).
出版者
出版者 Springer
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
出版タイプ
出版タイプ AO
出版タイプResource http://purl.org/coar/version/c_b1a7d7d4d402bcce
関連情報
識別子タイプ DOI
関連識別子 10.1007/s10875-020-00847-x
関連情報
識別子タイプ DOI
関連識別子 https://doi.org/10.1007/s10875-020-00847-x
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 0271-9142
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1573-2592
開始ページ
開始ページ 1065
書誌情報 Journal of Clinical Immunology
Journal of Clinical Immunology

巻 40, p. 1065-1081, 発行日 2020-08-27
旧ID 51510
戻る
0
views
See details
Views

Versions

Ver.1 2025-02-21 03:47:34.620272
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3